Definium Therapeutics (NASDAQ:DFTX) Stock: Insider Brandi Roberts Sells 3,377 Shares

Definium Therapeutics, Inc. (NASDAQ:DFTX) CFO Brandi Roberts sold 3,377 shares of the stock in a transaction that occurred on Friday, September 25th. The shares were sold at an average price of $36.57, for a total transaction of $123,496.89. Following the completion of the sale, the chief financial officer directly owned 394,528 shares of the company’s stock, valued at $14,427,888.96. This trade represents a 0.85% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Definium Therapeutics Stock Down 0.5%

Shares of DFTX traded down $0.20 during mid-day trading on Tuesday, reaching $38.21. 1,967,182 shares of the stock traded hands, compared to its average volume of 2,245,960. The stock has a fifty day simple moving average of $41.37 and a 200 day simple moving average of $32.06. Definium Therapeutics, Inc. has a 12-month low of $10.46 and a 12-month high of $49.70. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The firm has a market cap of $5.13 billion, a price-to-earnings ratio of -11.14 and a beta of 2.23.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Sell-side analysts expect that Definium Therapeutics, Inc. will post -3.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Definium Therapeutics

Several large investors have recently added to or reduced their stakes in the company. Nykredit A S acquired a new position in Definium Therapeutics in the second quarter worth $45,000. Allworth Financial LP acquired a new stake in shares of Definium Therapeutics during the second quarter worth $110,000. Integrated Wealth Concepts LLC bought a new position in shares of Definium Therapeutics in the 2nd quarter worth about $159,000. NewEdge Advisors LLC bought a new position in shares of Definium Therapeutics in the 2nd quarter worth about $222,000. Finally, WINTON GROUP Ltd acquired a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $240,000. 27.91% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

DFTX has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $66.00 target price on shares of Definium Therapeutics in a research report on Monday, September 14th. Bank of America initiated coverage on Definium Therapeutics in a report on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target for the company. Piper Sandler restated an “overweight” rating and set a $75.00 price objective (up from $73.00) on shares of Definium Therapeutics in a research note on Friday, August 7th. JonesTrading lifted their price objective on Definium Therapeutics from $74.00 to $90.00 and gave the stock a “buy” rating in a report on Thursday, August 13th. Finally, Wall Street Zen lowered Definium Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $64.88.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.